Task-evoked metabolic demands of the posteromedial default mode network are shaped by dorsal attention and frontoparietal control networks

  1. Godber M Godbersen
  2. Sebastian Klug
  3. Wolfgang Wadsak
  4. Verena Pichler
  5. Julia Raitanen
  6. Anna Rieckmann
  7. Lars Stiernman
  8. Luca Cocchi
  9. Mike Breakspears
  10. Marcus Hacker
  11. Rupert Lanzenberger
  12. Andreas Hahn  Is a corresponding author
  1. Medical University of Vienna, Austria
  2. University of Vienna, Austria
  3. Umeå University, Sweden
  4. QIMR Berghofer Medical Research Institute, Australia
  5. University of Newcastle Australia, Australia

Abstract

External tasks evoke characteristic fMRI BOLD signal deactivations in the default mode network (DMN). However, for the corresponding metabolic glucose demands both decreases and increases have been reported. To resolve this discrepancy, functional PET/MRI data from 50 healthy subjects performing Tetris® were combined with previously published data sets of working memory, visual and motor stimulation. We show that the glucose metabolism of the posteromedial DMN is dependent on the metabolic demands of the correspondingly engaged task-positive networks. Specifically, the dorsal attention and frontoparietal network shape the glucose metabolism of the posteromedial DMN in opposing directions. While tasks that mainly require an external focus of attention lead to a consistent downregulation of both metabolism and the BOLD signal in the posteromedial DMN, cognitive control during working memory requires a metabolically expensive BOLD suppression. This indicates that two types of BOLD deactivations with different-oxygen-to-glucose index may occur in this region. We further speculate that consistent downregulation of the two signals is mediated by decreased glutamate signaling, while divergence may be subject to active GABAergic inhibition. The results demonstrate that the DMN relates to cognitive processing in a flexible manner and does not always act as a cohesive task-negative network in isolation.

Data availability

Raw data will not be publicly available due to reasons of data protection. Sharing of raw data requires a data sharing agreement, approved by the departments of legal affairs and data clearing of the Medical University of Vienna. Details about this process can be obtained from the corresponding author. Processed data are available at Dryad https://doi.org/10.5061/dryad.5qfttdzbd. Custom code is available at GitHub https://github.com/NeuroimagingLabsMUV/Godbersen2023_eLife.

The following data sets were generated

Article and author information

Author details

  1. Godber M Godbersen

    Department of Psychiatry and Psychotherapy, Medical University of Vienna, Vienna, Austria
    Competing interests
    No competing interests declared.
  2. Sebastian Klug

    Department of Psychiatry and Psychotherapy, Medical University of Vienna, Vienna, Austria
    Competing interests
    No competing interests declared.
  3. Wolfgang Wadsak

    Department of Biomedical Imaging and Image-guided Therapy, Medical University of Vienna, Vienna, Austria
    Competing interests
    Wolfgang Wadsak, declares to having received speaker honoraria from the GE Healthcare and research grants from Ipsen Pharma, Eckert-Ziegler AG, Scintomics, and ITG; and working as a part time employee of CBmed Ltd. (Center for Biomarker Research in Medicine, Graz, Austria)..
  4. Verena Pichler

    Department of Pharmaceutical Sciences, University of Vienna, Vienna, Austria
    Competing interests
    No competing interests declared.
  5. Julia Raitanen

    Department of Biomedical Imaging and Image-guided Therapy, Medical University of Vienna, Vienna, Austria
    Competing interests
    No competing interests declared.
  6. Anna Rieckmann

    Umeå Center for Functional Brain Imaging, Umeå University, Umea, Sweden
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-5389-1578
  7. Lars Stiernman

    Department of Integrative Medical Biology, Umeå University, Umea, Sweden
    Competing interests
    No competing interests declared.
  8. Luca Cocchi

    Clinical Brain Networks Group, QIMR Berghofer Medical Research Institute, Brisbane, Australia
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-3651-2676
  9. Mike Breakspears

    School of Medicine and Public Health, University of Newcastle Australia, Brisbane, Australia
    Competing interests
    No competing interests declared.
  10. Marcus Hacker

    Department of Biomedical Imaging and Image-guided Therapy, Medical University of Vienna, Vienna, Austria
    Competing interests
    Marcus Hacker, received consulting fees and/or honoraria from Bayer Healthcare BMS, Eli Lilly, EZAG, GE Healthcare, Ipsen, ITM, Janssen, Roche, and Siemens Healthineers..
  11. Rupert Lanzenberger

    Department of Psychiatry and Psychotherapy, Medical University of Vienna, Vienna, Austria
    Competing interests
    Rupert Lanzenberger, received investigator-initiated research funding from Siemens Healthcare regarding clinical research using PET/MRI. He is a shareholder of the start-up company BM Health GmbH since 2019..
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-4641-9539
  12. Andreas Hahn

    Department of Psychiatry and Psychotherapy, Medical University of Vienna, Vienna, Austria
    For correspondence
    andreas.hahn@meduniwien.ac.at
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-9727-7580

Funding

Austrian Science Fund (KLI610)

  • Andreas Hahn

Medical University of Vienna (MDPhD Excellence Programm)

  • Sebastian Klug

European Research Council (ERC-STG-716065)

  • Anna Rieckmann
  • Lars Stiernman

National Health and Medical Research Council (GN2001283)

  • Luca Cocchi

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Reviewing Editor

  1. Shella Keilholz, Emory University and Georgia Institute of Technology, United States

Ethics

Human subjects: All participants provided written informed consent after a detailed explanation of the study protocol, they were insured and reimbursed for participation. The study was approved by the Ethics Committee of the Medical University of Vienna (ethics number 1479/2015) and procedures were carried out according to the Declaration of Helsinki. The study was pre-registered at ClinicalTrials.gov (NCT03485066).

Version history

  1. Preprint posted: August 12, 2022 (view preprint)
  2. Received: November 3, 2022
  3. Accepted: May 3, 2023
  4. Accepted Manuscript published: May 25, 2023 (version 1)
  5. Accepted Manuscript updated: May 26, 2023 (version 2)
  6. Version of Record published: May 30, 2023 (version 3)

Copyright

© 2023, Godbersen et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 704
    Page views
  • 117
    Downloads
  • 2
    Citations

Article citation count generated by polling the highest count across the following sources: Crossref, PubMed Central, Scopus.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Godber M Godbersen
  2. Sebastian Klug
  3. Wolfgang Wadsak
  4. Verena Pichler
  5. Julia Raitanen
  6. Anna Rieckmann
  7. Lars Stiernman
  8. Luca Cocchi
  9. Mike Breakspears
  10. Marcus Hacker
  11. Rupert Lanzenberger
  12. Andreas Hahn
(2023)
Task-evoked metabolic demands of the posteromedial default mode network are shaped by dorsal attention and frontoparietal control networks
eLife 12:e84683.
https://doi.org/10.7554/eLife.84683

Share this article

https://doi.org/10.7554/eLife.84683

Further reading

    1. Neuroscience
    Daichi Sasaki, Ken Imai ... Ko Matsui
    Research Article

    The presence of global synchronization of vasomotion induced by oscillating visual stimuli was identified in the mouse brain. Endogenous autofluorescence was used and the vessel ‘shadow’ was quantified to evaluate the magnitude of the frequency-locked vasomotion. This method allows vasomotion to be easily quantified in non-transgenic wild-type mice using either the wide-field macro-zoom microscopy or the deep-brain fiber photometry methods. Vertical stripes horizontally oscillating at a low temporal frequency (0.25 Hz) were presented to the awake mouse, and oscillatory vasomotion locked to the temporal frequency of the visual stimulation was induced not only in the primary visual cortex but across a wide surface area of the cortex and the cerebellum. The visually induced vasomotion adapted to a wide range of stimulation parameters. Repeated trials of the visual stimulus presentations resulted in the plastic entrainment of vasomotion. Horizontally oscillating visual stimulus is known to induce horizontal optokinetic response (HOKR). The amplitude of the eye movement is known to increase with repeated training sessions, and the flocculus region of the cerebellum is known to be essential for this learning to occur. Here, we show a strong correlation between the average HOKR performance gain and the vasomotion entrainment magnitude in the cerebellar flocculus. Therefore, the plasticity of vasomotion and neuronal circuits appeared to occur in parallel. Efficient energy delivery by the entrained vasomotion may contribute to meeting the energy demand for increased coordinated neuronal activity and the subsequent neuronal circuit reorganization.

    1. Medicine
    2. Neuroscience
    Flora Moujaes, Jie Lisa Ji ... Alan Anticevic
    Research Article

    Background:

    Ketamine has emerged as one of the most promising therapies for treatment-resistant depression. However, inter-individual variability in response to ketamine is still not well understood and it is unclear how ketamine’s molecular mechanisms connect to its neural and behavioral effects.

    Methods:

    We conducted a single-blind placebo-controlled study, with participants blinded to their treatment condition. 40 healthy participants received acute ketamine (initial bolus 0.23 mg/kg, continuous infusion 0.58 mg/kg/hr). We quantified resting-state functional connectivity via data-driven global brain connectivity and related it to individual ketamine-induced symptom variation and cortical gene expression targets.

    Results:

    We found that: (i) both the neural and behavioral effects of acute ketamine are multi-dimensional, reflecting robust inter-individual variability; (ii) ketamine’s data-driven principal neural gradient effect matched somatostatin (SST) and parvalbumin (PVALB) cortical gene expression patterns in humans, while the mean effect did not; and (iii) behavioral data-driven individual symptom variation mapped onto distinct neural gradients of ketamine, which were resolvable at the single-subject level.

    Conclusions:

    These results highlight the importance of considering individual behavioral and neural variation in response to ketamine. They also have implications for the development of individually precise pharmacological biomarkers for treatment selection in psychiatry.

    Funding:

    This study was supported by NIH grants DP5OD012109-01 (A.A.), 1U01MH121766 (A.A.), R01MH112746 (J.D.M.), 5R01MH112189 (A.A.), 5R01MH108590 (A.A.), NIAAA grant 2P50AA012870-11 (A.A.); NSF NeuroNex grant 2015276 (J.D.M.); Brain and Behavior Research Foundation Young Investigator Award (A.A.); SFARI Pilot Award (J.D.M., A.A.); Heffter Research Institute (Grant No. 1–190420) (FXV, KHP); Swiss Neuromatrix Foundation (Grant No. 2016–0111) (FXV, KHP); Swiss National Science Foundation under the framework of Neuron Cofund (Grant No. 01EW1908) (KHP); Usona Institute (2015 – 2056) (FXV).

    Clinical trial number:

    NCT03842800